(HNI) HNI - NYSE
Sector: Consumer Cyclical | Industry: Furnishings, Fixtures & Appliances | Exchange: NYSE (USA) | Market Cap: 2.361m USD | Total Return: -25.3% in 12m
Avg Turnover: 21.6M
EPS Trend: 90.3%
Qual. Beats: 0
Rev. Trend: 79.8%
Qual. Beats: 0
Warnings
P/E ratio 121.4
High Debt/EBITDA (8.7) with thin interest coverage (1.3)
Tailwinds
No distinct edge detected
HNI Corporation is a Muscatine, Iowa-based manufacturer operating in two distinct categories: Workplace Furnishings and Residential Building Products. The company designs and markets a broad portfolio of office furniture, including seating, storage, and collaborative systems, alongside a specialized residential segment focused on wood, gas, and electric hearth products.
The business model relies on a multi-channel distribution strategy, utilizing independent dealers, wholesalers, and direct-to-government sales to reach end-users. In the office furniture sector, demand is historically cyclical and closely tied to white-collar employment levels and corporate capital expenditure budgets. The residential segment benefits from a dominant position in the hearth industry, where high barriers to entry exist due to complex safety regulations and established distribution networks.
Investors can further examine valuation metrics and historical performance for this ticker on ValueRay. Founded in 1944, HNI maintains a diverse brand portfolio including HON, Allsteel, and Kimball, positioning it as a major player in the North American commercial interior and home improvement markets.
- White-collar employment levels and return-to-office trends drive workplace furnishings demand
- New housing starts and remodeling activity dictate residential building product sales
- Integration of Kimball International acquisition influences long-term operating margin expansion
- Rising raw material costs for steel and foam impact manufacturing profitability
- Corporate capital expenditure budgets determine large-scale contract furniture procurement cycles
| Net Income: 1.40m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -9.95 > 1.0 |
| NWC/Revenue: 10.06% < 20% (prev 3.37%; Δ 6.69% < -1%) |
| CFO/TA 0.02 > 3% & CFO 91.9m > Net Income 1.40m |
| Net Debt (1.93b) to EBITDA (222.4m): 8.69 < 3 |
| Current Ratio: 1.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.1m) vs 12m ago -1.88% < -2% |
| Gross Margin: 38.73% > 18% (prev 39.91%; Δ -1.18% > 0.5%) |
| Asset Turnover: 108.2% > 50% (prev 136.6%; Δ -28.41% > 0%) |
| Interest Coverage Ratio: 1.33 > 6 (EBIT TTM 65.6m / Interest Expense TTM 49.4m) |
| A: 0.08 (Total Current Assets 1.30b - Total Current Liabilities 936.1m) / Total Assets 4.77b |
| B: 0.11 (Retained Earnings 526.5m / Total Assets 4.77b) |
| C: 0.02 (EBIT TTM 65.6m / Avg Total Assets 3.32b) |
| D: 0.59 (Book Value of Equity 1.77b / Total Liabilities 3.00b) |
| Altman-Z'' = 1.61 = BB |
| DSRI: 1.66 (Receivables 555.7m/237.3m, Revenue 3.59b/2.54b) |
| GMI: 1.03 (GM 39.91% / 38.73%) |
| AQI: 1.23 (AQ_t 0.45 / AQ_t-1 0.37) |
| SGI: 1.41 (Revenue 3.59b / 2.54b) |
| TATA: -0.02 (NI 1.40m - CFO 91.9m) / TA 4.77b) |
| Beneish M = -2.02 (Cap -4..+1) = BB |
As of June 24, 2026, the stock is trading at USD 34.25 with a total of 452,641 shares traded. Over the past week, the price has changed by +4.93%, over one month by +10.43%, over three months by -5.51% and over the past year by -25.25%.
Current recommended Stop Loss: 30.80 (which is 10.1% or 2.4 ATR below the current price).
HNI has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy HNI.
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 69 | 101.5% |
P/E Trailing = 121.4444
P/E Forward = 8.1699
P/S = 0.6582
P/B = 1.3249
P/EG = 0.4085
Revenue TTM = 3.59b USD
EBIT TTM = 65.6m USD
EBITDA TTM = 222.4m USD
Long Term Debt = 1.43b USD (from longTermDebt, last quarter)
Short Term Debt = 87.0m USD (from shortTermDebt, last quarter)
Debt = 2.01b USD (from shortLongTermDebtTotal, last quarter) + Leases 282.5m
Net Debt = 1.93b USD (calculated: Debt 2.01b - CCE 78.2m)
Enterprise Value = 4.29b USD (2.36b + Debt 2.01b - CCE 78.2m)
Interest Coverage Ratio = 1.33 (Ebit TTM 65.6m / Interest Expense TTM 49.4m)
EV/FCF = 550.3x (Enterprise Value 4.29b / FCF TTM 7.80m)
FCF Yield = 0.18% (FCF TTM 7.80m / Enterprise Value 4.29b)
FCF Margin = 0.22% (FCF TTM 7.80m / Revenue TTM 3.59b)
Net Margin = 0.04% (Net Income TTM 1.40m / Revenue TTM 3.59b)
Gross Margin = 38.73% ((Revenue TTM 3.59b - Cost of Revenue TTM 2.20b) / Revenue TTM)
Gross Margin QoQ = 34.60% (prev 39.88%)
Tobins Q-Ratio = 0.90 (Enterprise Value 4.29b / Total Assets 4.77b)
Interest Expense / Debt = 2.46% (Interest Expense 49.4m / Debt 2.01b)
Taxrate = 40.20% (36.5m / 90.8m)
NOPAT = 39.2m (EBIT 65.6m * (1 - 40.20%))
Current Ratio = 1.39 (Total Current Assets 1.30b / Total Current Liabilities 936.1m)
Debt / Equity = 1.13 (Debt 2.01b / totalStockholderEquity, last quarter 1.77b)
Debt / EBITDA = 8.69 (Net Debt 1.93b / EBITDA 222.4m)
Debt / FCF = 247.7 (Net Debt 1.93b / FCF TTM 7.80m)
Total Stockholder Equity = 1.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.04% (Net Income 1.40m / Total Assets 4.77b)
RoE = 0.11% (Net Income TTM 1.40m / Total Stockholder Equity 1.31b)
RoCE = 2.39% (EBIT 65.6m / Capital Employed (Equity 1.31b + L.T.Debt 1.43b))
RoIC = 1.02% (NOPAT 39.2m / Invested Capital 3.85b)
WACC = 5.58% (E(2.36b)/V(4.37b) * Re(9.08%) + D(2.01b)/V(4.37b) * Rd(2.46%) * (1-Tc(0.40)))
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -45.35 | Cagr: -0.56%
[DCF] Terminal Value 73.10% ; FCFF base≈79.8m ; Y1≈70.0m ; Y5≈56.6m
[DCF] Fair Price = N/A (negative equity: EV 908.0m - Net Debt 1.93b = -1.02b; debt exceeds intrinsic value)
EPS Correlation: 90.25 | EPS CAGR: 19.59% | SUE: 0.48 | # QB: 0
Revenue Correlation: 79.83 | Revenue CAGR: 11.15% | SUE: -0.37 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.04 | Chg30d=-9.78% | Revisions=-25% | Analysts=4
EPS next Quarter (2026-09-30): EPS=1.31 | Chg30d=-8.25% | Revisions=-50% | Analysts=4
EPS current Year (2026-12-31): EPS=4.02 | Chg30d=-1.59% | Revisions=-25% | GrowthEPS=+16.3% | GrowthRev=+111.3%
EPS next Year (2027-12-31): EPS=4.83 | Chg30d=+0.21% | Revisions=-14% | GrowthEPS=+20.2% | GrowthRev=+4.0%
[Analyst] Revisions Ratio: -50%